Analyst Jason Butler of JMP Securities reiterated a Buy rating on Precigen (PGEN – Research Report), with a price target of $7.00. Jason ...
3h
Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Zevra Therapeutics (ZVRA – Research Report). The associated ...
Halozyme Therapeutics (NASDAQ:HALO) fell 14% after confirming on Thursday that it made an €11 per share bid for Evotec .
Anavex Life Sciences' (AVXL) stock surged on new Alzheimer's trial data, but data's inconsistency raises concerns, making the ...
Piper Sandler initiates coverage of Nektar Therapeutics, citing REZPEG's Treg-focused action as a potential breakthrough for ...
On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed data from a two-and-a-half-year interim analysis from the ongoing ...
Meanwhile, Leerink Partners maintained their Outperform rating for Keros Therapeutics, citing the potential of another drug, cibotercept, to differentiate itself from competing treatments.
JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...
while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy ...
while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy ...
Highmark Health, Alignment Health and Network Health are on an exclusive list of Medicare Advantage carriers with five-star ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback